All In Biotech

Drug Trial Radar · NCT05383183

Efficacy and Safety of ChOline ALfoscerate in Patient With Mild to Moderate Alzheimer's Disease

A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase IV Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate in Patients With Mild to Moderate Alzheimer's Disease

Last checked: Nov 20, 2026Latest source record: Mar 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 630 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

630

Planned (sponsor's estimate)

Start

Jan 20, 2022

Primary completion

Jun 30, 2025

Study completion Dec 9, 2025

Sponsor

Lead sponsor
Daewoong Bio Inc.Industry
Sponsor type
Industry
First posted
May 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether combination of donepezil, a cholinesterase inhibitor, with choline alfoscerate has a more favourable clinical profile than monotherapy with donepezil alone.

Conditions

  • Alzheimer Disease

Interventions

  • Choline Alfoscerate 400mgDrug

    Oral administration

  • PlaceboDrug

    Oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in ADAS-Cog scoresTime frame: 48 weeks from baseline

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Changwon Fatima Hospital

    Changwon, South Korea · Recruiting

  • Gachon University Gil Medical Center

    Incheon, South Korea · Recruiting

  • CHA Bundang Medical Center

    Seongnam, South Korea · Recruiting

  • The Catholic University of Korea Seoul ST.MARY'S Hospital

    Seoul, South Korea · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.